Venture Funding Deals: Tenaya's $92m, Nuvation's $275m Lead October Rounds

08 Nov 2019

• By Deanna Kamienski, Beth Allan, and Maureen Riordan

Former Medivation CEO David Hung launched stealthy oncology start-up Nuvation with $275m in series A venture capital, while Tenaya's series B brought in $92m for small molecules as well as cell and gene therapies to treat cardiovascular diseases.

Venture Funding Deals: Tenaya's $92m, Nuvation's $275m Lead October Rounds

More from Deals

More from Business